아토사 제네틱스(ATOS)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $2.60 (+1.56%), 시가총액 $0.05B, 52주 범위 $0.56 ~ $6.17.
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.
아토사 제네틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.
아토사 제네틱스의 현재 주가는 $2.60 (+1.56%)입니다. BlackQuant에서 실시간 시세와 차트를 확인할 수 있습니다.
아토사 제네틱스의 시가총액은 약 $0.05B입니다.
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (